Diabetes-related biomarkers and methods of use thereof
First Claim
Patent Images
1. A method for monitoring a treatment regimen to delay or prevent an individual'"'"'s conversion to a frank Diabetes disease state, the method comprising:
- (a) obtaining from at least one biological sample isolated from said individual undergoing said treatment regimen measurements of biomarkers comprising the biomarkers ADIPOQ (Adiponectin), GLUCOSE and CRP (C-Reactive Protein), and further comprising at least one biomarker selected from the group consisting of HBA1C (Glycosylated Hemoglobin), IGFBP1 (Insulin-like growth factor binding protein
1), IGFBP2 (Insulin-like growth factor binding protein
2), Insulin, LEP (Leptin) and TRIG (Triglycerides);
(b) calculating the individual'"'"'s risk for developing a diabetic condition from the output of a model, wherein the inputs to said model comprise said measurements, and further wherein said model was developed by fitting data from a longitudinal study of a selected population of individuals and said fitted data comprises levels of said biomarkers and conversion to Diabetes in said selected population of individuals; and
(c) comparing the calculated risk for said individual to a previously calculated risk obtained from at least one earlier sample from said individual.
6 Assignments
0 Petitions
Accused Products
Abstract
The invention describes biomarkers which can be used to predict the likelihood that an individual will develop Diabetes. The biomarkers can also be used to screen large groups in order to identify individuals at risk of developing Diabetes.
153 Citations
38 Claims
-
1. A method for monitoring a treatment regimen to delay or prevent an individual'"'"'s conversion to a frank Diabetes disease state, the method comprising:
-
(a) obtaining from at least one biological sample isolated from said individual undergoing said treatment regimen measurements of biomarkers comprising the biomarkers ADIPOQ (Adiponectin), GLUCOSE and CRP (C-Reactive Protein), and further comprising at least one biomarker selected from the group consisting of HBA1C (Glycosylated Hemoglobin), IGFBP1 (Insulin-like growth factor binding protein
1), IGFBP2 (Insulin-like growth factor binding protein
2), Insulin, LEP (Leptin) and TRIG (Triglycerides);(b) calculating the individual'"'"'s risk for developing a diabetic condition from the output of a model, wherein the inputs to said model comprise said measurements, and further wherein said model was developed by fitting data from a longitudinal study of a selected population of individuals and said fitted data comprises levels of said biomarkers and conversion to Diabetes in said selected population of individuals; and (c) comparing the calculated risk for said individual to a previously calculated risk obtained from at least one earlier sample from said individual. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)
-
-
15. A method for monitoring a treatment regimen or to delay, or prevent an individual'"'"'s conversion to a frank Diabetes disease state, the method comprising:
-
(a) obtaining from at least one biological sample isolated from said individual undergoing said treatment regimen measurements of biomarkers comprising the biomarkers ADIPOQ (Adiponectin), GLUCOSE and CRP (C-Reactive Protein), and further comprising at least one biomarker selected from the group consisting of HBA1C (Glycosylated Hemoglobin), IGFBP1 (Insulin-like growth factor binding protein
1), IGFBP2 (Insulin-like growth factor binding protein
2), Insulin, LEP (Leptin) and TRIG (Triglycerides);(b) calculating the individual'"'"'s risk for developing a diabetic condition from the output of a model, wherein the inputs to said model comprise said measurements, and further wherein said model was developed by fitting data from a longitudinal study of a selected population of individuals and said fitted data comprises levels of said biomarkers and conversion to Diabetes in said selected population of individuals; (c) storing said calculated risk on electronic data storage means (d) comparing the calculated risk for said individual to a previously calculated risk obtained from at least one earlier sample from said individual. - View Dependent Claims (16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 30, 31, 32, 33, 34, 35, 36, 37, 38)
-
-
29. A method for monitoring a treatment regimen to delay or prevent an individual'"'"'s conversion to a frank Diabetes disease state, the method comprising:
-
(a) obtaining from at least one biological sample isolated from said individual undergoing said treatment regimen measurements of biomarkers comprising the biomarkers ADIPOQ (Adiponectin), GLUCOSE and CRP (C-Reactive Protein), and further comprising at least one biomarker selected from the group consisting of HBA1C (Glycosylated Hemoglobin), IGFBP1 (Insulin-like growth factor binding protein
1), IGFBP2 (Insulin-like growth factor binding protein
2), Insulin, LEP (Leptin) and TRIG (Triglycerides);(b) calculating the individual'"'"'s risk for developing a diabetic condition from the output of a model, wherein the inputs to said model comprise said measurements, and further wherein said model was developed by fitting data from a longitudinal study of a selected population of individuals and said fitted data comprises levels of said biomarkers and conversion to Diabetes in said selected population of individuals; (c) storing said calculated risk on electronic data storage means (d) comparing the calculated risk for said individual to a previously calculated risk obtained from at least one earlier sample from said individual and (f) advising said individual or a health care practitioner of whether there has been a change in calculated risk.
-
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeTrue Health Diagnostics LLC (True Health Group LLC)
-
Original AssigneeTethys Bioscience, Inc.
-
InventorsUrdea, Michael S., McKenna, Michael P., Arensdorf, Patrick A.
-
Primary Examiner(s)COOK, LISA V
-
Application NumberUS13/253,578Publication NumberTime in Patent Office545 DaysField of SearchNoneUS Class Current435/7.21CPC Class CodesG01N 2800/042 Disorders of carbohydrate m...G01N 2800/52 Predicting or monitoring th...G01N 33/48714 for determining substances ...G01N 33/6893 related to diseases not pro...G16H 50/30 for calculating health indi...Y02A 90/10 Information and communicati...
